43 results
DEFA14A
INVA
Innoviva Inc
17 May 23
Additional proxy soliciting materials
5:18pm
of Social Capital Suvretta Holdings Corp. II (Nasdaq: DNAB), a publicly traded special purpose acquisition company where she has been a director since 2021 … . Social Capital Suvretta Holdings Corp. II filed a Current Report on Form 8-K to such effect on May 16, 2023, which is incorporated herein by reference
SC TO-T
EX-99
LJPC
La Jolla Pharmaceutical Co.
25 Jul 22
Third party tender offer statement
8:34am
:
(Include Zip Code)
(Tax Identification or Social Security Number)
☐ Credit Shares tendered by book-entry transfer that are not accepted … (full title):
Address:
(Include Zip Code)
Area Code and Telephone Number:
Email Address:
Tax Identification or Social Security No.:
GUARANTEE
8-K
EX-10.1
bj0wg2e79mqi257ecw61
13 Jul 22
Entry into a Material Definitive Agreement
5:27pm
SC TO-C
EX-2.1
bmahbfxvrb2g4ya7ej6v
11 Jul 22
Information about tender offer
3:46pm
8-K
EX-2.1
injy5iexsd2d6
11 Jul 22
Innoviva to Acquire La Jolla Pharmaceutical Company
7:38am
425
28ul8w
11 Jul 22
Business combination disclosure
7:38am
SC TO-T
EX-99
d1mjhdi6z
7 Jun 22
Third party tender offer statement
9:04am
SC TO-C
EX-2.1
l91 5znrsos0uct5eb
23 May 22
Information about tender offer
8:53pm
8-K
EX-2.1
4gj7 1ffl30a19
23 May 22
Tender and Support Agreement
8:51pm
8-K
EX-4.1
ohldmudo rhr45q5cm
8 Mar 22
Innoviva Announces Proposed Offering of $200 Million of Convertible Senior Notes
5:15pm
8-K
EX-10.2
sigkr
4 Oct 18
Departure of Directors or Certain Officers
5:21pm
8-K
EX-10.1
kjk f7ut3
4 Oct 18
Departure of Directors or Certain Officers
5:21pm
8-K
EX-10.1
f3yno
8 Aug 18
Departure of Directors or Certain Officers
4:44pm
8-K
EX-10.3
xkr7a5
5 Jun 14
Theravance, Inc. and Theravance Biopharma, Inc. Announce
12:00am
8-K
EX-10.3
or6 zq61l2f
21 Apr 14
Theravance Closes Private Placement of $450 Million of 9% Non-Recourse Notes Supporting Strategic Separation Process
12:00am
SC 14D9
EX-99
kmsowyrxap
1 Aug 07
Tender offer solicitation
12:00am